UroGen Pharma is performing  safety and efficacy clinical trials in several urinary tract indications: UTUC and bladder cancer in leading centers in USA, Europe and Israel:

UTUCBack to top

olympus

The OLYMPUS study –  Optimized DeLivery of Mitomycin for Primary UTUC Study
A  Study Evaluating The Feasibility, Safety, Durability and Ablative Effect of MITOGEL™ (mitomycin) urothelial gel, 0.4% in Patients With Low Grade Upper Tract Urothelial Cancer.
Currently recruiting patients.

Read more

LOW GRADE BLADDER CANCERBack to top

 optima 

The OPTIMA study – OPTimized Instillation of Mitomycin for BlAdder Cancer Treament. A Prospective, Open Label, Comparative Dose Escalation Study Evaluating the Chemoablative Effect of  Intravesical Instillation of VESIGEL™ (mitomycin) urothelial gel, 0.18% in Patients with Non Muscle Invasive Bladder Cancer (NMIBC).
Study conducted in Europe and Israel. COMPLETED 


The OPTIMA study II – OPTimized Instillation of Mitomycin for BlAdder Cancer Treament. A Prospective, Open Label Study Evaluating the Chemoablative Effect of  Intravesical Instillation of VESIGEL™ (mitomycin) urothelial gel, 0.18% in Patients with Non Muscle Invasive Bladder Cancer (NMIBC).
Commencement of patient recruitment planned for H1 2018.

CARCINOMA IN SITUBack to top

Pilot, Open-label, phase II study, investigating the response to intravesical TMX‑101 VESIMUNE™ (imiquimod) in patients with CIS bladder cancer. Phase I study under IND.
COMPLETED

-